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Rapid detection of Mycobacterium tuberculosis (Mtb), an etiological agent of tuberculosis (TB), is
important for global control of this disease. Aptamers have emerged as a potential rival for antibodies in
therapeutics, diagnostics and biosensing due to their inherent characteristics. The aim of the current
study was to select and characterize single-stranded DNA aptamers against MPT64 protein, one of the
predominant secreted proteins of Mtb pathogen. Aptamers speciﬁc to MPT64 protein were selected
in vitro using systematic evolution of ligands through exponential enrichment (SELEX) method. The
selection was started with a pool of ssDNA library with randomized 40-nucleotide region. A total of 10
cycles were performed and seventeen aptamers with unique sequences were identiﬁed by sequencing.
Dot Blot analysis was performed to monitor the SELEX process and to conduct the preliminary tests on
the afﬁnity and speciﬁcity of aptamers. Enzyme linked oligonucleotide assay (ELONA) showed that most
of the aptamers were speciﬁc to the MPT64 protein with a linear correlation of R2 ¼ 0.94 for the most
selective. Using Surface Plasmon Resonance (SPR), dissociation equilibrium constant KD of 8.92 nM was
obtained. Bioinformatics analysis of the most speciﬁc aptamers revealed the existence of a conserved as
well as distinct sequences and possible binding site on MPT64. The speciﬁcity was determined by testing
non-target ESAT-6 and CFP-10. Negligible cross-reactivity conﬁrmed the high speciﬁcity of the selected
aptamer. The selected aptamer was further tested on clinical sputum samples using ELONA and had
sensitivity and speciﬁcity of 91.3% and 90%, respectively. Microscopy, culture positivity and nucleotide
ampliﬁcation methods were used as reference standards. The aptamers studied could be further used for
the development of medical diagnostic tools and detection assays for Mtb.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) remains one of the main causes of human
death around the globe. According to the World Health Organiza-
tion (WHO), 2015 recorded the highest TB cases than in previous
years. 9.6 million people were infected, and 1.5 million people died
of TB in 2014 [1]. Themortality rate for patients infected with active
TB goes beyond 50% when not diagnosed, hence, rapid and accurate
diagnostics coupled with further prompt treatment of the disease isa).
Ltd. This is an open access article uthe cornerstone for controlling TB outbreaks. An early detection of
TB would allow fast recovery, therefore, reducing the number of
fatal cases. However, TB detection remains a signiﬁcant healthcare
issue in the developing countries owing to a number of challenges.
Firstly, mycobacterium is a slow-growing bacterium, it takes 4e8
weeks to cultivate on traditional solid media, and 10e14 days even
with rapid liquid culture [2]. Secondly, pulmonary TB causes low
clinical symptoms early in the course of disease, leading to a delay
in seeking patient care. Thirdly, active pulmonary TB may present a
low bacillary burden at the early stage, which often leads to low
sensitivity for sputum smear microscopy commonly used in the
developing countries [3]. Therefore, it is important to develop a fastnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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technologies and advances over the last decades in biosensing, the
development of simple point-of-care tests in the near future is still
challenging.
The most promising approach for developing such biosensor
could be based on the detection of antigens or Mtb DNA speciﬁc
to TB. Antigen speciﬁc for TB diagnostic is based on the detection
of abundantly secreted proteins with high levels of immunoge-
nicity [4]. The predominant immunogenic secreted proteins of
Mtb are 23 kDa MPT64, 6 kDa early secreted antigenic targets
(ESAT-6) and 10 kDa culture ﬁltrate protein (CFP-10). These
proteins were used as antigens in skin patch test [5], immuno-
chromatography assays [6] and immunohistochemical analysis
[7] and were detected based on antibody detection methods. The
sensitivity of such diagnostic tools in clinical specimens could be
high; however, the use of antibodies as recognition elements has
some limitations [8].
An alternative to antibodies are aptamers, which are single
stranded oligonucleotides (both DNA and RNA) that have abilities
to speciﬁcally bind to a broad range of targets [9e11] with high
afﬁnity and speciﬁcity [12]. Aptamers are synthesized in vitro us-
ing a method called systematic evolution of ligands by exponential
enrichment (SELEX) [9]. This method includes three main stages:
incubation of a random library with the target; separation of
bound aptamers from unbound ones; ampliﬁcation of bound se-
quences using PCR [12]. Aptamer technology has interesting ad-
vantages over antibodies. For example, aptamers are synthesized
in vitro from a library that contains large numbers of random se-
quences; thus, alleviating the use of animals during selection
process compared to antibodies. The properties of aptamers can be
tuned on demand and, therefore, be selected to bind speciﬁc tar-
gets in non-physiological conditions or targets that are non-
immunogenic and toxic to animals. The production of selected
aptamers is performed using chemical synthesis, optimizing their
purity while reducing eventual batch-to-batch variations.
Furthermore, once the selection process is over, they can be
massively synthesized lowering their cost compared to antibody
production. Aptamers made from nucleic acids are more stable
than antibodies, and they can be stored at ambient temperatures.
In addition, they are smaller in size, and their afﬁnities are not
affected by labelling [13e15]. Due to these properties, aptamers
are used in areas such as functional studies of proteins, thera-
peutics, diagnostics and biosensing [12,16]. For biosensing,
aptamers are very promising because they can be selected and
used under any pre-deﬁned conditions, and they can be easily
immobilized to obtain a custom-made surface.
Taking into consideration advantages of aptamers in di-
agnostics, aptamers have been selected against TB related anti-
bodies [19e21] and predominant secreted antigens ESAT-6, CFP-10
[17] MPT64 [18]. Aptamer selected against antigens ESAT-6 and
CFP-10 [17] showed that aptamer CSIR 2.11 had sensitivity and
speciﬁcity of 100% and 68.75%, respectively. Selected aptamer was
tested on clinical sputum samples with KD values being at nM range
indicating a strong binding. Aptamers selected against antigen
MPT64 were 35 nucleotides long and had 86.3% sensitivity and
88.5% speciﬁcity [22]. The selection was based on immobilising the
protein on ELISA wells and consequent aptamer binding, elution
and ampliﬁcation. Aptamers in this study were not tested on clin-
ical sputum samples as in previous study with ESAT-6 and CFP-10
but tested on diluted bacterial culture ﬁltrates. There was neither
information presented on cross reactivity with other relevant
proteins that are abundant in culture ﬁltrates nor the information
on KD values.
The main goal of our research was to select and characterize
ssDNA aptamers that speciﬁcally bind to MPT64 protein of Mtbusing SELEX technology based on capturing the aptamer-protein
complex on a nitrocellulose membrane and consequent elution
and ampliﬁcation. The results revealed that one aptamer had the
highest binding afﬁnity when evaluated and characterized with
SPR (surface plasmon resonance) and ELONA (Enzyme Linked
Oligonucleotide Assay). The selected aptamer is 40 nucleotides
long and has different sequence from previously published work
[22]. It can distinguish MPT64 protein among other mycobacterial
secreted proteins, such as ESAT-6 and CFP-10 and also has
improved sensitivity and speciﬁcity (91.3% and 90%, respectively).
The selected aptamers could be used for the TB diagnosis in a
multiplexed assay along with other aptamers that have been
previously selected against other TB antigens such as ESAT-6 and
CFP-10.
2. Materials and methods
Fig. 1 illustrates the principles and concepts of selection and
characterization of MPT64 aptamers, and the ﬁve major steps of the
experiments: in vitro selection of aptamer candidates against
MPT64 using SELEX method; dot blot analysis of afﬁnity of the pool
of aptamers from selected SELEX rounds and aptamers with known
sequences; cloning, sequencing, and bioinformatics analysis of
aptamers; and detection of MPT64 in buffer and clinical sputum
samples using ELONA. The methods are described below.
2.1. Proteins
Target immunogenic protein MPT64 (46 kDa) (Rv1980c) (Gene
ID: 581375; Accession#: CAA53143) of Mtb H37Rv strain with a
concentration of 1 mg/ml was obtained from EnoGene Biotech Co
Ltd (Nanjing, China). His and Trx tagged MPT64 protein was puri-
ﬁed from recombinant Escherichia coli strain by afﬁnity chroma-
tography with >90% purity. According to manufacture, the protein
is suitable for use in multiple immunoassay formats, including
ELISA, Western Blot and Rapid Tests. Non-target ESAT-6 (p463-1)
and CFP-10 (p460-1) proteins were purchased from Sunny lab
(USA).
2.2. DNA library, primers
The oligonucleotide template was synthesized as a single-
stranded 80-mer with the following sequence: 50- TCA CTT CAA
ATG TGC GCT TCeN40e CGT CAA AAC AGGGGGTAGAA - 30 where
the central 40 nucleotides represent random oligonucleotides
based on equal incorporation of A, T, G and C at each position. The
dsDNAs were obtained by PCR ampliﬁcation using Forward 50- TCA
CTT CAA ATG TGC GCT TC-30 and Reverse 50- TTC TAC CCC CTG TTT
TGA CG -30 primers. Biotinylated forward primer for Dot-blot
analysis and phosphorylated reverse primers to obtain ssDNAs by
lambda exonuclease digestion were of the same sequences as for-
ward and reverse primers. Both the library and primers were syn-
thesized and PAGE puriﬁed by Integrated DNA Technologies
(Coralville, IA, USA).
2.3. In vitro selection of aptamers
Aptamer candidates against MPT64 were selected using the
SELEX protocol based on [23] with slight modiﬁcations. SELEX is
an oligonucleotide-based combinatorial library approach which
has been extensively used to isolate aptamers against various
targets including proteins, ions, cells and surface epitopes [11,24].
This method includes three main stages: incubation of a random
library with the target; separation of bound aptamers from un-
bound ones; ampliﬁcation of bound sequences using PCR [12]
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cycle through a pre-wetted nitrocellulose acetate membrane
(0.45 mm HAWP ﬁlter, Millipore, MA, USA) in a ﬁlter holderFig. 1. Schematic representation of principles and concepts of selection and charac-
terization of MPT64 aptamers using SELEX, dot blot, cloning, sequencing, and ELONA
techniques.(“pop-top”, diameter 13 mm, Millipore) in order to exclude ﬁlter-
binding ssDNA sequences from the library. To initiate in vitro
selection, ssDNA library was denatured at 95 C for 10 min in a
thermocycler (Mastercycler gradient, Eppendorf) and was
allowed to be cooled down approximately to 34e38 C inside the
thermocycler. Denatured DNAs were then incubated with the
target protein at 15 rpm on a variable speed rotor (Grant Bio PTR-
30, Keison) for 1 h and 45 min at room temperature (for the ﬁrst
cycle). This reaction mixture was then ﬁltered over a HAWP ﬁlter
and washed with binding buffer (50 mM Tris-HCl; 25 mM NaCl;
5 mM MgCl2; 10 mM DTT; pH 7.5). ssDNA that was retained with
the protein on a ﬁlter were eluted with elution buffer (0.4 M
sodium acetate, 5 mM EDTA, and 7 M urea, pH 5.5) at 70e80 C
for 5 min twice. Afterwards, the eluted DNA was diluted with an
equal volume of dH2O and was precipitated with ethanol and
ammonium acetate and incubated for 1 h at 80 C. After
centrifugation at 13,000 rpm at 4 C for 1 h, supernatant was
discarded, and pellet was washed twice with 75% ethanol solu-
tion and resuspended in dH2O for further PCR. Ampliﬁcation
conditions were as follow: initial denaturation at 95 C for 5 min
and ﬁnal extension at 72 C for 10 min; and 30 cycles of dena-
turation at 95 C for 30 s; annealing at 58 C for 45 s and
extension at 72 C for 45 s. Ampliﬁed products were analyzed on
non-denaturing 6% Tris-borate EDTA (TBE)-polyacrylamide gels
(Invitrogen, CA, USA) at 200 V for 20 min after binding with SYBR
Green 1 (Invitrogen, CA, USA). ssDNA was obtained by digestion
of PCR products ampliﬁed with phosphorylated reverse primers
with 5 units of lambda exonuclease (New England Biolabs, Ips-
wich, MA, USA) per 50 ml reaction. Reaction was done for 1 h at
37 C and then heat inactivated for 10 min at 72 C. Digested
products were precipitated as above (resuspension of pellet in
binding buffer) and used for the next round of SELEX. 10 itera-
tions of SELEX were performed. For additional rounds of selec-
tion, the amount of protein was reduced twice in each cycle:
from 4.35 mg to 0.07 mg in a binding buffer (total volume of
150 ml). Incubation time was in range from 1 h 45 min for the ﬁrst
cycle and 40 min for the last. Incubation conditions as well as
concentrations of target protein and ssDNA are listed in Table 1.
Concentration of ssDNA was measured using NanoDrop 1000
Spectrophotometer (ThermoScientiﬁc, DE, USA). All procedures
(where applicable) were performed in a biosafety level 2 cabinet
(Puriﬁer Delta Series Class II, Type A2 Biological Safety Cabinet,
Labconco Corporation, MO, USA).
2.4. Dot blot analysis
Dot blot is a technique that enables identiﬁcation and analysis of
proteins of interest where sample proteins are spotted onto
membrane and hybridized with a probe. The successful interaction
results in colored spots (Fig. 1). Dot blot in this study was used for aTable 1
Concentrations of ssDNA and target MPT64 used in in vitro selection of aptamers.
SELEX cycle Target MPT64 (mg) ssDNA pool (mg) Incubation time (min)
1 4.35 35 105
2 2.17 ~30 90
3 1.08 ~30 60
4 0.54 ~30 60
5 0.27 2.9 60
6 0.13 7.1 50
7 0.07 ~7 40
8 0.04 10 40
9 0.03 10 40
10 0.03 10 40
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SELEX rounds and aptamers with known sequences. Selected SELEX
DNA products were ampliﬁed using forward biotin-labeled primers
and phosphorylated reverse primers with further digestion using
lambda exonuclease to obtain biotinylated ssDNA. MPT64 protein
was applied onto a nitrocellulose membrane (BA85 Protran,
0.45 mm, Whatman, USA) in different concentrations (87, 8.7, and
0.87 mg/ml) for dot blot analysis of SELEX products. For dot blot
analysis with known aptamer sequences, 500, 250, 100, 50, 25, 10,
5, and 1 mg/ml of MPT64 proteinwas applied onto the nitrocellulose
membrane. After immobilization on themembrane, blocking buffer
(casein 12.5 g; NaCl 4.5 g; Tris 605 mg; Thimerosal 100 mg) was
applied for 45e60 min, and 475 ml of 817 ng biotinylated aptamers
from selected cycles were left to incubate for 30 min. After washing
three times with 1  KPL (KPL, Gaithersburg, Maryland) washing
solution (0.002 M imidazole, 0.02% Tween20, 0.5 mM EDTA,
160 mM NaCl) the membrane reacted with streptavidin-alkaline
phosphatase diluted to 1:500 for 30 min. The membrane was
then coated in BCIP/NBT (5-Bromo-4-chloro-3-indoxyl-phosphate
and nitroblue tetrazolium) (KPL, MD, USA) substrate for 15 min in
the dark after washing. The results were determined by observation
of violet stained spots on the membrane (Fig. 2b, c). Escherichia coli
antibodies labeled with biotin served as a positive control (diluted
at 1:500) (Meridian Life sciences, ME, USA), and deionized water
served as a negative control.
2.5. Cloning
The aptamer pools from SELEX rounds were puriﬁed on either
6% TBE gel (Invitrogen) or using Qiaquick PCR Puriﬁcation Kit
(Qiagen, Germany), ligated to pGEM®-T Vector System II and
transformed into JM109 High Efﬁciency Competent Cells according
to the manufacturer's manual (Promega, USA) and then incubated
at 37 C overnight. White colonies were picked and streaked on a
plate. Individual colonies of the transformed cells were propagated
in 5 ml of LB broth with ampicillin (50 mg/ml) for 15 h at 37 C. The
cells were harvested by centrifugation at 8000 rpm for 5 min, and
plasmid DNAwas extracted using the QIAprepMiniprep kit (Qiagen,
Germany). Ampicillin and IPTG used in cloning were purchased
from Calbiochem (San Diego, CA, USA); X-Gal (5-bromo-4-chloro-
3-indolyl-b-D-galactoside) and S.O.C mediumwere purchased from
Invitrogen. The purity of puriﬁed plasmids was analyzed by
NanoDrop 1000 Spectrophotometer, and, then, the plasmids were
sent for sequencing.
2.6. Sequencing and bioinformatics analysis of aptamers
Sequencing of plasmid DNA of the selected transformants wasFig. 2. (a) 6% TBE-PAGE analysis of PCR products from cycle 6 of in vitro selection of aptamers
of SELEX cycle 6, Lane 2. 25 bp DNA ladder (Invitrogen); (b) Dot blot analysis of afﬁnity bindi
(c) Afﬁnity evaluation of the ssDNA aptamer sequence (4) using dot blot analysis method. “þ
deionized water.done by automated DNA sequencing using ABI 3130xl analyzer Big
dye 3.1 diemistry (ABI 7300 Sequence Detector, Foster City, CA).
Analysis of aptamer sequences nucleotide content, repeats and
inverse complementary repeats were performed. For every selected
aptamer, we computed all sites having mutually reverse comple-
mentary sequences and formed by three and more nucleotides.
Sequence repeats within and between selected aptamers were
computed as well. The secondary structures of sequenced aptamers
were predicted by web-based OligoAnalyzer 3.1 tool from IDT (In-
tegrated DNA Technologies, https://www.idtdna.com/calc/
analyzer). Analysis of putative G quadruplex structures were car-
ried out on a web-based server for predicting G-quadruplexes in
nucleotide sequences (http://bioinformatics.ramapo.edu/QGRS/
analyze.php). The analysis of surface charges for MPT64 protein
was based on data obtained from protein database (RCSB Protein
data bank). PDB database contained only one record 2HHI for Mtb
MPT64 protein, resolved by solution NMR [25]. Electrostatic surface
potential of 2HHI models were computed by DelPhi Web Server
(http://compbio.clemson.edu/sapp/delphi_webserver/) using
AMBER parameters and Linear solver MPT64 2HHI model structure
and accessible surface area and residues for potential binding site
were analyzed.
2.7. Detection of protein with an aptamer based sandwich enzyme
linked oligonucleotide assay (ELONA)
ELONA is a plate-based assay designed for detection and
quantiﬁcation of complexes, where a protein is immobilized to a
solid surface and, then, complexed with biotinylated aptamer [26].
The complex is assessed by the absorbance change upon addition
of a substrate (Fig. 1). Seventeen identiﬁed aptamer sequences
were further tested for their binding to target MPT64 using ELONA
based on protocol [17] with modiﬁcations. Non-target CFP-10 and
ESAT-6 proteins were used as controls. Each biotinylated ssDNA
used in the assay was custom synthesized (Sigma). Ninety-six well
plates (Bioster, A947978) were coated with 500 ng of protein in
100 ml of 100 mM Na2CO3 buffer overnight at 4 C. After blocking
with 1% BSA (Fisher Scientiﬁc, BPE1600-100) for 1 h at 4 C the
wells were washed 4 times with 1  TBS buffer (24.2 g Tris Base,
80 g NaCl, pH 7.6), and biotin labeled ssDNA aptamers (500 nM)
were added to each well and incubated for 2 h at 37 C. The wells
were then washed 4 times with 1  TBS buffer (24.2 g Tris Base,
80 g NaCl, pH 7.6 for 1 L). Streptavidin-horseradish peroxidase
conjugate (Thermo Scientiﬁc, NE170004) was diluted in 1:10000
in TBS buffer and 100 ml was applied and incubated for 30 min at
37 C. Then, 50 ml of Turbo-3,305,50-tetramethylbenzene (TMB,
Sigma T8665) was added to each well and incubated for 15 min at
37 C. The reaction was quenched by adding 50 ml of 1 M H2SO4,against target MPT64 by SELEX method stained with SYBR Green I: Lane 1. PCR product
ng between aptamer pools from the SELEX cycle 5 and target MPT64, and two controls;
” control Escherichia coli antibodies labeled with biotin (diluted at 1:500), “-” control -
M. Sypabekova et al. / Tuberculosis 104 (2017) 70e7874and protein-aptamer complex was quantiﬁed by determining the
absorbance at 450 nm using MultiScan FC (Thermo Scientiﬁc)
(Fig. 1). In the background control, MPT64, CFP-10 and ESAT-6
were coated on the wells but none of the ssDNA aptamers were
added. For each sample the optical density at 450 nm (OD) of
background was subtracted from the OD value of the experimental
sample.
2.8. Determination of the dissociation constant (KD) of aptamers
BIAcore X100 SPR instrument with SA chips (GE Healthcare,
Austria, Vienna) was used to determine the afﬁnity of the ssDNA
aptamer sequence (17) to MPT64 protein in kinetic studies. All
experiments were conducted at 25 C with ﬂow rate of 10 ml/min.
HBS-EP buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA,
0.005% v/v Surfactant P20) was used as the running buffer and
12 mM NaOH (10 ml) was used as a regeneration buffer to remove
the bound target. Selected biotinylated aptamers were immobi-
lized onto the surface of the streptavidin coated SA chip at a
concentration of 1 mM for 10 min and followed by injecting
10 mM of biotin for 5 min and ethanolamine-HCl (1 M, pH 8.5) as
blocking reagents. The ﬂow cell with ethanolamine-HCl blocking,
but without aptamer immobilization, was used as a control to
subtract non-speciﬁc binding. MPT64 proteins with different
concentrations (2.5, 5, 10, 20, and 40 mg/ml) were injected over
the sensor chip, and the afﬁnity binding was monitored for 2 min
followed by washing with running buffer. The evaluation was
done using BiaEvaluation software (Biacore) by 1:1 [Langmuir]
ﬁtting model.
2.9. MPT64 antigen detection in sputum samples
Case controlled study was performed to determine the speci-
ﬁcity of aptamers with the highest binding capacity to MPT64. We
obtained 43 sputum samples, 20 from patients with deﬁnite pres-
ence ofMtb and 23 from non-tuberculous controls. Clinical samples
were obtained from regional Tuberculosis hospital (Astana,
Kazakhstan). Patients were diagnosed with Mtb by phthisiatrician
based on the criteria of Kazakhstani preventive measures on
tuberculosis. The sputum samples from the hospital conﬁrmed the
presence of M. tuberculosis in infected patient samples using
ZiehleNeelsen stain and culturing at 37 C in Lowenstein-Jensen
medium and Bactec MGIT for mycobacteria testing. Method of
sputum liquefaction was same as in Ref. [27] with modiﬁcations.
Brieﬂy, 0.4 M NaOH solutions was added into equal volume of
human sputum samples. The suspension was vortexed brieﬂy.
Subsequently, suspension from each tube was transferred to an
empty tube, and 1 M HEPES buffer was added to each tube to
neutralize the NaOH. The samples were then introduced onto the
ninety-six well plates and left overnight at 4 C. ELONA was per-
formed to determine whether aptamer was able to detect the
presence of MPT64 in sputum samples. The surface of microtiter
plates was blocked using 1% BSA solution for 1 h at 4 C. The wells
were then washed 4 times with 1  TBS. Biotinylated aptamer se-
quences (16) and (17) in concentration of 500 nM were added to
each well and incubated for 2 h at 37 C. In the background, control
sputum samples were coated on the wells but none of the ssDNA
aptamers were added. For each sample the optical density at
450 nm (OD) of background was subtracted from the OD value of
the experimental sample. ELONA results were then used for spec-
iﬁcity and sensitivity comparison using 43 sputum samples, where
each sputum sample was tested in triplicate. The results were
averaged and the standard deviation was calculated for each
sputum sample.2.10. Statistical analysis
All statistical analyses were performed using Graphpad Prism
6 (Graphpad Software, Inc). The diagnostic value of the assay
using aptamers was evaluated using Receiver Operating
Characteristics (ROC) curve analysis (Graphpad Prism 6, Graph-
pad Software, Inc). OD values for ELONA assay were plotted
and the area under the curves (AUC) and 95% conﬁdence
intervals (95% CIs) were calculated. The optimal cut-points were
determined based on maximum value of Youden's index
(YI ¼ speciﬁcity þ sensitivity  1).
3. Results
3.1. In vitro selection of aptamers
A random ssDNA library of about 1014 aptamers was screened
for their efﬁciency to bind target MPT64. A commercially available
MPT64 protein (Rv1980c) of Mtb H37Rv strain was used as the
target. Following incubation, the bound oligonucleotides were
separated from unbound ones via nitrocellulose ﬁltration as
described in the Methods section. Target-bound aptamers were
eluted from the ﬁlters, and enriched at each selection round by
ampliﬁcation using PCR. After each round of selection the obtained
DNAs were quantiﬁed by spectrophotometer and analyzed by PAGE
gel. Fig. 2a shows the PAGE gel of the 6th round of selectionwith an
expected 80bp DNA size. A total of ten rounds of repeated
separation-ampliﬁcation cycles were completed in order to receive
high afﬁnity and speciﬁcity of MPT64 DNA aptamers.
Obtaining pure ssDNA is an important step during in vitro se-
lection. We chose to use lambda exonuclease as it was shown to
improve the SELEX efﬁciency and ﬁnal purity of the ssDNA solu-
tions, compared with the methods involving streptavidin-coated
magnetic beads and further alkaline treatment [28].
As a rapid assessment, dot blot analysis was performed after
SELEX rounds for evaluation of binding afﬁnity to the target
MPT64. In this regard, target MPT64 was spotted onto the nitro-
cellulose membrane in different concentrations, air-dried at room
temperature, and then incubated with biotinylated aptamer pool
from the 5th cycle. E. coli antibodies labeled with biotin served as
a positive control, and deionized water served as a negative
control. The results of dot blot assay for the aptamer pool at the
5th cycle is presented in Fig. 2b. Violet stained spots on the
nitrocellulose membrane (Fig. 2b) indicated the binding reaction
between target protein and aptamer pool and developed a clear
dot for the target MPT64 with a concentration of 87 mg/ml, while
showed a faint dot for the concentration 8.7 mg/ml. With the in-
crease of selection cycles, the selected aptamer pools showed
stronger binding to the target with the increase of both dot size
and intensity. Only after this conﬁrmation, the next SELEX cycle
was conducted. An afﬁnity evaluation of obtained individual
aptamers with known sequences was performed using the dot
blot assay as well. Target protein in different concentrations was
immobilized on the surface of the nitrocellulose membrane,
which was further incubated with biotinylated aptamer sequence
(4). The amount of enzyme-linked conjugate bound was assayed
by incubating the strip with an appropriate chromogenic sub-
strate leading to a color development. Therefore, ssDNA aptamers
were deemed to react with target protein when the strips showed
purple dots. Fig. 2c shows the dot blot afﬁnity analysis for the
aptamer sequence (4). The intensity of the violet stained spots
increased with increasing concentrations of the selected aptamer
(4), indicating that indeed the aptamer had an afﬁnity to the
target.
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Cloning and sequencing of aptamer pools from ten rounds of
SELEX cycles revealed seventeen aptamers with unique sequences.
We further analyzed the sequences of aptamers (16) and (17) since
they were the most speciﬁc to MPT64 as it was shown in an ELONA
assay (Fig. 3b). Computed GC/AT ratio (G þ C)/(A þ T) of all
seventeen aptamers varies from 0.21 to 1.5, knowing that selected
aptamer sequences (16) and (17) have GC/AT ratio of about 1.11.
Aptamers (16) and (17) had the longest common TCCAGT sequence
which was present once in each aptamer. Position of this sequence
is similar in predicted secondary structures, based onWatson-Crick
pairing A-T and G-C, for aptamers (16) and (17). In both aptamers
this sequence is located within the biggest potential stem loop
(hairpin), formed by fourWatson-Crick base pairs in stem parts and
having 6/4 bases in loop part for aptamer sequences (17) and (16),
respectively. In both aptamers (16) and (17), the GT sufﬁx of this
sequence belongs to the stem of the loop. Selected aptamer se-
quences do not have known G quadruplex motifs as found in anti-
thrombin aptamer [29]. The GC/AT ratio is one of the basic sequence
characteristics in terms of nucleotide composition and in future
studies, aptamer sequences could be modiﬁed and optimized tak-
ing into account this ratio.
Surface charge analysis for the target MPT64 model (PDB codeFig. 3. Binding afﬁnity of selected ssDNA aptamers to proteins MPT64, ESAT-6, CFP-10. Bindin
10 was determined by an ELONA assay. Binding of the ssDNA aptamers to ESAT-6 and CFP-10
were incubated in wells coated with target MPT64, and non-target ESAT-6 and CFP-10. Apta
ELONA analysis of the relative binding abilities of individual aptamer sequences (1e17). (c)
means of ±SEMs (n ¼ 3).2hhi) showed positively charged hydrophilic amino acids, such as
arginine (ARG85 and ARG117) and lysine (LYS118), were found to be
grouped allowing a potential binding site for the negatively
charged DNA backbone.
3.3. Evaluation and characterization of DNA aptamers
ELONA was used to determine the binding interaction between
the selected aptamer sequences and the target MPT64. Non-target
M. tuberculosis immunogenic secreted proteins ESAT-6 and CFP-10
with a concentration of 500 ng/ml was also tested to check any
cross-reactivity. Experiments were conducted in six replicates. A
general pattern shows that all aptamers have higher binding to the
target MPT64 compared to non-target ESAT-6 and CFP-10 (Fig. 3a,
supplem.mat/Fig. 1). As can be observed from Fig. 3a, speciﬁcity of
aptamer sequence (17) is presented in red circles for target and
non-target proteins, where OD value for both non-target proteins
was signiﬁcantly lower (P < 0,0001) in comparison to the target.
ELONA analysis of the relative binding abilities of individual
aptamer sequences (1e17) was further analyzed. This was done by
subtracting the absorbance of MPT64-aptamer complex by the
highest absorbance of either aptamer-ESAT-6 or aptamer-CFP-10
complexes (Fig. 3b). The negative value for aptamer sequence (10)
shows that the oligonucleotide preferentially binds to either ESAT-6g of biotinylated ssDNA aptamers to the target MPT64, and non-target ESAT-6 and CFP-
is shown for comparative purposes. (a) Individual aptamer sequences (1e17) (500 nM)
mers (17) are shown in circles. All data are shown as the means of ±SEMs (n ¼ 6). (b)
Binding of the aptamer sequence (17) to the target MPT64. All data are shown as the
M. Sypabekova et al. / Tuberculosis 104 (2017) 70e7876or CFP-10 and not to target MPT64. Aptamer sequence (17) showed
the highest binding to target MPT64 rather than to non-target
proteins used in this assay (Fig. 3b). Therefore, aptamer sequence
(17) was chosen for further assessment. The dose response analysis
for the aptamer sequence (17) showed an increase in absorbance
signal from concentration ranging from 12 nM to 250 nM. There
was no further increase observed after 250 nM indicating that the
surface was saturated above this concentration (Fig. 3c). A linear
correlation was found between OD450 value and aptamer sequence
(17) in a range of concentration (Fig. 3c). The regression equation
for OD450 difference versus aptamer (17) concentration was
y ¼ 0.1436xþ0.056 with R2 ¼ 0.94, where x is the concentration of
aptamer sequence (17) in nM (Fig. 3c). The result showed that the
selected aptamer could be used as a recognition ligand to detect
target MPT64.
Surface plasmon resonance (SPR) is a technique used to follow
the dynamics of interactions between a target molecule immo-
bilized on a biochip and a ligand introduced in solution. It allows
apparent kinetic constants to be estimated for the formation of a
speciﬁc complex and a quantitative estimation of the afﬁnity of
the ligand for the target molecule to be calculated. In this study,
SPR was used to identify the afﬁnity of the selected aptamer
sequence (17) against target MPT64. Immobilization of the
aptamer was based on streptavidin-biotin interaction. SPR signal
reached 1510.8 RU after injecting a biotinylated aptamer over a
sensor chip coated with streptavidin, indicating immobilization of
the aptamer on the sensor surface via biotin to streptavidin in-
teractions. MPT64 protein at different concentrations (2.5, 5, 10,
20, 40 mg/ml) was injected on the sensor chip so the association
and dissociation of the complex could be monitored as a function
of time. The protein was injected at increasing concentrations
over the aptamer coated surface and the reference was taken
directly on the surface without aptamer. The analytical signal was
computed as the difference between the signals (resonance units,
RU) detected on the aptamer surface and on the reference. An
overlay of the SPR signal from the interactions between aptamer
(17) and the target MPT64 is shown in Fig. 4. With increasing
MPT64 concentrations there was also an increase in RU. The
calculated ka (association rate constant) for aptamer sequence (17)
was 9.93  104 (M1 s1) and kd (dissociation rate constant) was
8.85  104 (s1) and KD (dissociation equilibrium constant) was
8.92 nM. The binding kinetics of the immobilized ssDNA aptamers
to MPT64 protein was determined using BiaCore X100 surface
plasmon resonance.
3.4. MPT64 antigen detection in sputum samples
Forty-three sputum samples were used to evaluate aptamer
sequences (16) and (17) for detecting TB infection in caseFig. 4. An overlay of the SPR signals from the interaction between the target and
aptamers (17). In each case, the protein was injected over immobilized aptamers (17)
with an initial concentration of 2.5, followed by 5, 10, 20 and 40 mg/ml.controlled study using ELONA. Aptamer (16) was the second in
line for speciﬁc MPT64 binding, and it was used for comparison
purposes. It was found that OD450 values were signiﬁcantly higher
in those patients with active TB than in healthy individuals
(Fig. 5a, p  0.0001). Twenty of sputum samples had a conﬁrmed
TB and twenty-three samples were obtained from healthy in-
dividuals. The speciﬁcity and sensitivity of the sputum sample
analysis based on aptamer (17) by ELONA were calculated as 90%
(96 CI: 68.3e98.7%) and 91.3% (95% CI: 71.96e98.93%), respec-
tively, using Youden's index. The AUC was 94.78% (95% CI:
89e100%) from the ROC curve (Fig. 5b). The speciﬁcity and
sensitivity for aptamer (16) was 75% (95% CI: 50.9e91.34%) and
100% (95% CI: 85.75e100%), respectively. The AUC for aptamer (16)
was 95% (95% CI: 89.37e100%) (Fig. 5c).
4. Discussion and conclusion
Theoretically, the DNA library used during this study could
potentially contain up to 440 or 1024 different sequences, since the
diversity of an oligonucleotide library is 4n, where n is the length of
the oligonucleotides [11]. However, in practice 1016 sequences are
usually used [30]. Nevertheless, this is still much higher than
possible murine antibodies of 109 to 1011. This large range of se-
quences gives an opportunity to select ligands with a very high
afﬁnity [11]. The stability of aptamers in various temperatures
ﬂuctuations offers another advantage, as they are tolerant to harsh
chemicals and biological conditions as compared to antibodies. In
addition to low cost production and variability by modiﬁcations,
aptamer in several studies showed to be extremely speciﬁc and
sensitive being able to detect down to pM and fM range [31e33]. To
achieve this concentration range, an antifouling surface chemistry
of aptamers on the surfaces needs to be carefully tuned and opti-
mized for better detection. These parameters could greatly enhance
both sensitivity and speciﬁcity of the aptasensor [32,33], where the
detection limit could be lowered below the current clinical value
detection.
In this study, aptamers against Mtb secreted protein MPT64
were successfully selected and could be used as an alternative for
detection and diagnosis of TB for in ﬁeld or on-site application. The
selected aptamer showed a good speciﬁcity and sensitivity values;
therefore, they would likely be less prone to give false positive
results. The selected aptamer could also be used in a multiplexed
assay for TB diagnosis alongside with other aptamers selected
against ESAT-6, CFP-10 and surface saccharides of Mtb. Previous
study with ESAT-6 and CFP-10 showed that the binding of some
aptamers could be abrogated by the presence of anti-MPT64 anti-
body by possibly competing to the same binding site [17]. In
addition, due to the steric hindrance and the size difference be-
tween aptamer and antibody, the information obtained from
ELONA i.e. absorbance value would be different as well. Therefore,
current study did not compare the binding process of aptamer-
MPT64 with that of antibody-MPT64. The comparison could be
done after optimizing the surface chemistry for aptamer and
measuring the values using different techniques, such as electro-
chemical impedance spectroscopy. In case of low signal, aptamers
could be modiﬁed easily such as labeling with magnetic/gold
nanoparticles or with ﬂuorescent reporting molecules, which offer
a great potential for the development of aptamer based detection
technologies for rapid, cost effective and reliable detection method
for TB diagnosis. Additional NMR, colorimetry studies and further
bioinformatics analysis and aptamer manipulation could be con-
ducted for improved biosensor applications. For future studies, the
speciﬁcity and sensitivity test could be validated by testing sputum
samples from chronic patients with no TB infection, such as
asthmatic.
Fig. 5. Detection of MPT64 antigens in sputum samples. (a) ELONA based assay for the detection of MPT64 antigens in TB infected and healthy individuals using aptamer sequences
(16) and (17); (b, c) The ROC curve of aptamer sequences (17) and (16), respectively, based on ELONA for sputum samples.
M. Sypabekova et al. / Tuberculosis 104 (2017) 70e78 77In conclusion, selected ssDNA aptamer bounded speciﬁcally to
the target MPT64 using the SELEX technology. Selected aptamers
further showed a strong binding afﬁnity with high speciﬁcity
against Mtb secreted protein MPT64. Future research will focus on
optimizing the surface chemistry for the development of a sensor
using the selected aptamers as bio-recognition elements for TB
diagnosis.
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